Adjuvant therapy in adrenocortical carcinoma: prognostic factors and treatment options.

ABSTRACT: Adrenocortical carcinoma (ACC) is a rare cancer with high recurrence rates and heterogeneous clinical behavior. The role of adjuvant therapy remains unclear because of the challenges in collecting high-quality data for a rare cancer. The current treatment recommendations and guidelines for adjuvant therapy are mostly derived retrospectively from national databases and the treatment outcomes of patients seen in referral centers. To better select patients for adjuvant therapy, multiple factors need to be considered including staging, markers of cellular proliferation (such as Ki67%), resection margins, hormonal function, and possibly genetic alterations of the tumor as well as patient-related factors such as age and performance status. Adjuvant mitotane remains the most commonly used adjuvan

SUBMITTER: Al-Ward R 

PROVIDER: S-EPMC10259337 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature